Details

Autor(en) / Beteiligte

• Liu, Jason B.
• Ramonell, Kimberly M.
• Carty, Sally E.
• McCoy, Kelly L.
• Schaitkin, Barry M.
• Karslioglu-French, Esra
• Morariu, Elena M.
• Ohori, N. Paul
• Seethala, Raja R.
• Chiosea, Simion I.
• Nikiforova, Marina N.
• Nikiforov, Yuri E.
• Yip, Linwah

Titel

Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes

Ist Teil von

• Surgery, 2023-01, Vol.173 (1), p.252-259

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Molecular testing improves the diagnostic accuracy of thyroid cancer. Whether specific molecular testing results are associated with tumor phenotype or provide prognostic information needs further delineation. Consecutive thyroid cancer patients after index thyroidectomy with ThyroSeq version 3 (Rye Brook, NY) molecular testing obtained on preoperative fine-needle aspiration or thyroidectomy specimens from patients with thyroid cancer were categorized into 3 molecular risk groups based on detected mutations, fusions, copy number alterations, and/or gene expression alterations and correlated with histopathology and recurrence, defined as biochemical or structural. Of 578 patients, 49.9%, 37.5%, and 12.6% had molecular risk group–low, molecular risk group–intermediate, and molecular risk group–high cancers, respectively. With a median 19-month follow-up, 9.1% patients recurred. Compared with molecular risk group–low, molecular risk group–intermediate cancers were diagnosed in younger patients and more often had microscopic extrathyroidal extension, involved margins, and nodal disease. Compared with molecular risk group–intermediate, molecular risk group–high cancers were diagnosed in older patients and more often had gross extrathyroidal extension and vascular invasion. In multivariable analysis, recurrence was more likely in molecular risk group–high cancers than in molecular risk group–intermediate (hazard ratio = 4.0; 95% confidence interval, 1.9–8.6; P < .001) and more likely in molecular risk group–intermediate than in molecular risk group–low (hazard ratio = 5.0; 95% confidence interval, 2.0–12.5; P < .001). Using modern comprehensive genotyping, the genetic profile of thyroid cancers can be categorized into 3 novel molecular risk groups that were associated with histopathologic phenotype and recurrence in short-term follow-up.